Navigation Links
EntreMed Announces 2008 Corporate and Clinical Program Priorities
Date:3/13/2008

ording, dial 800-642-1687 (U.S. or Canada) or 706-645- 9291 (internationally) and enter the digital pin number 37155333. An audio replay will also be available approximately two hours after the conference and can be accessed through the Company's website at http://www.entremed.com. EntreMed's fourth quarter update call was held today at 10:00 a.m. ET. A digital recording will be available approximately two hours after completion of the conference and will be accessible for 60 days. To access the recording, dial 800-642-1687 (U.S. or Canada) or 706-645-9291 (internationally) and enter the digital pin number 37155333. In addition, an audio replay will also be available on the Company's website at http://www.entremed.com approximately one hour after the conclusion of the live conference.

About EntreMed

EntreMed, Inc. is a clinical-stage pharmaceutical company developing therapeutic candidates primarily for the treatment of cancer and inflammation. MKC-1 is currently in multiple Phase 2 clinical trials for cancer. MKC-1 is an oral cell-cycle regulator with activity against the mTOR pathway. ENMD-1198, a novel tubulin-binding agent, is in Phase 1 studies in advanced cancers. The Company has approved IND applications for Panzem(R) in rheumatoid arthritis, and ENMD-2076, a dual-acting Aurora-angiogenesis inhibitor, for cancer. EntreMed's goal is to develop and commercialize new compounds based on the Company's expertise in angiogenesis, cell-cycle regulation and inflammation - processes vital to the treatment of cancer and other diseases, such as rheumatoid arthritis. Additional information about EntreMed is available on the Company's web site at http://www.entremed.com and in various filings with the Securities and Exchange Commission.

Forward Looking Statements

This release contains forward
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. EntreMed Reports Fourth Quarter and Year-End 2007 Financial Results
2. EntreMed to Present at BIO CEO and Investor Conference
3. EntreMed Presents Interim Results for Phase 2 Carcinoid Tumor Study
4. EntreMed Announces FDA Acceptance of IND Application for Aurora Kinase/Angiogenesis Inhibitor, ENMD-2076
5. EntreMed Appoints Senior Vice President of Research and Development
6. EntreMed to Present at ThinkEquity Partners 5th Annual Growth Conference
7. Arpida Announces Full Year 2007 Financial Results
8. Innocoll Announces Dosing of First Patient in a Second US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain
9. WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results
10. Exelixis Announces March 17 Webcast of Presentation at the Cowen and Company Annual Health Care Conference
11. deCODE Genetics Announces Full-year 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Village, Calif. (PRWEB) January 15, 2014 ... treatment and management through the genomic analysis of tumor ... offer Therapy Finder™, a web-based cancer decision support application ... reporting option with Cynvenio’s ClearID™ genomic test, Therapy Finder ...
(Date:1/15/2014)... Toronto, Canada (PRWEB) January 15, 2014 ... perspectives on nonclinical and clinical safety assessment in biosimilars. ... a path for biosimilar drug development, however the complex ... regards to quality, safety and efficacy extremely challenging. Based ...
(Date:1/15/2014)... 15, 2014 Two champions of science, ... sponsorship of an annual competition for middle and high ... to, innovative STEM study. The competition presents students with ... of Engineering Aptitude, Mathematics, and Sciences is a ...
(Date:1/15/2014)... 2013 was a banner year of continued ... saw continued independent research led by the team at ... $1 million grant from the Susanne Marcus Collins Foundation, ... peer reviewed journal, Amy Grant highlighted Brainwave Optimization® in ...
Breaking Biology Technology:Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 3Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 4Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 5Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 3
... deal from January through March this year, according to the ... state said that the lack of deals in a quarter ... another reminder that capital is hard to come by. , ... sometimes adding up to around $20 million or $25 million, ...
... America's health care costs continue to rise, the need ... potential of the Internet has never been more urgent. ... Exchange (WHIE) has joined more than 150 statewide ... task of creating localized systems in which clinics, hospitals, ...
... , ,Two companies enter into an agreement to develop software, ... service provider deliver a range of services in the information ... the parties come to the end of the engagement reasonably ... , ,However, sometimes the agreement goes astray and disputes ...
Cached Biology Technology:Money Tree survey shows lull in Wisconsin venture capital deals 2Money Tree survey shows lull in Wisconsin venture capital deals 3Wisconsin Health Information Exchange shares burden of electronic medical records 2Wisconsin Health Information Exchange shares burden of electronic medical records 3Wisconsin Health Information Exchange shares burden of electronic medical records 4Wisconsin Health Information Exchange shares burden of electronic medical records 5Arbitration can help when IT deals go sour 2Arbitration can help when IT deals go sour 3
(Date:7/9/2014)... With over 100 diseases that can attack soybean ... of the most wanted list? University of Illinois scientists ... more research is needed on the fungus that causes ... cool, damp growing conditions but Macrophomina phaseolina , ... dry drought conditions. , "As the climate continues to ...
(Date:7/9/2014)... cooks are turning to more healthful alternatives to their ... sometimes mean low satisfaction. Now researchers are reporting new ... that are made with olive oil rather than pork ... of Agricultural and Food Chemistry . , Ana M. ... to expect just the right amount of chewiness and ...
(Date:7/9/2014)... of Adlie penguins shows that the population is ... than previously estimated. Adlie penguins have long been ... understand the effects of climate change and fishing ... satellite imagery, researchers from Stony Brook University and ... that permits regular monitoring of Adlie penguins across ...
Breaking Biology News(10 mins):Climate change provides good growing conditions for charcoal rot in soybeans 2Climate change provides good growing conditions for charcoal rot in soybeans 3New study finds that Adélie penguin population is on the rise 2New study finds that Adélie penguin population is on the rise 3
... modeling and paleontological evidence as a crystal ball, 18 ... on a much worse collision course with Mother Nature ... state-shift in Earth,s biosphere, a paper just published in ... multitude of disciplines, suggest our planet,s ecosystems are careening ...
... that live zebrafish can be influenced by engineered robots. ... Bioinspiration and Biomimetics , provide a stepping stone on the ... monitor and control fish behaviour. In the future, water-based ... and the control of pest species. ...
... Researchers who were looking for organisms that eke out ... Earth have found a hardy few. A new DNA analysis ... in South America has revealed a handful of bacteria, fungi, ... a different way of converting energy than their cousins elsewhere ...
Cached Biology News:Study predicts imminent irreversible planetary collapse 2Engineered robot interacts with live fish 2AGU: Unique microbes found in extreme environment 2AGU: Unique microbes found in extreme environment 3AGU: Unique microbes found in extreme environment 4
Mouse monoclonal [MLM544] to cardiac Myosin light chain 1 ( Abpromise for all tested applications). entrezGeneID: 4634 SwissProtID: P08590...
Request Info...
Mouse monoclonal [J53] to Thyroid Hormone Receptor beta 1 ( Abpromise for all tested applications). entrezGeneID: 7068 SwissProtID: P10828...
Polyclonal Antibody to TRIB1/ SKIP1/ Tribbles 1...
Biology Products: